Somatostatin-14 | Buy Online | Growth Hormone Inhibitor Guide

Dr. Roger Guillemin stared at the chromatography readout in disbelief. After years of grinding through sheep hypothalamus tissue, extracting and purifying countless fractions, he'd finally isolated the mysterious factor that shut down growth hormone release. The date was 1973, and the 14-amino-acid peptide on his bench would reshape our understanding of hormonal regulation forever.

What Guillemin discovered wasn't just another peptide — it was the master switch for growth hormone control. Somatostatin-14, the native hypothalamic peptide, doesn't just inhibit growth hormone. It orchestrates an entire symphony of hormonal suppression, affecting everything from insulin to gastrin to thyroid-stimulating hormone.

Today, researchers studying metabolic disorders, acromegaly, and neuroendocrine tumors rely on somatostatin-14 as both a research tool and a therapeutic foundation. But understanding this peptide requires going beyond its basic inhibitory function — it's about grasping how the body's most sophisticated regulatory systems actually work.

The Discovery: Hunting the Growth Hormone Brake

The story begins in the 1960s with a puzzle. Scientists knew growth hormone releasing hormone (GHRH) existed, but growth hormone levels didn't match the simple "on switch" model. Something was actively suppressing GH release between pulses.

Guillemin's team at the Salk Institute spent seven years processing over 500,000 sheep hypothalami. They weren't looking for somatostatin specifically — they were chasing what they called "somatotropin release-inhibiting factor" (SRIF). The name describes exactly what it does: it stops somatotropin (growth hormone) release.

The breakthrough came when they isolated a fraction that consistently shut down GH secretion in pituitary cell cultures. Sequencing revealed a cyclic 14-amino-acid peptide with a disulfide bridge between two cysteine residues. The structure was elegant: Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys.

Guillemin shared the 1977 Nobel Prize in Physiology or Medicine for this discovery, but the real impact came from what researchers found next. Somatostatin wasn't just in the hypothalamus — it was everywhere. Pancreatic delta cells. Gastric mucosa. Intestinal tissues. The peripheral nervous system.

This wasn't a simple brain peptide. It was a fundamental regulatory molecule that evolution had deployed throughout the body wherever precise hormonal control was needed.

Chemical Identity: The Cyclic Regulator

Somatostatin-14 (also called SST-14 or SRIF-14) has the molecular formula C76H104N18O19S2 with a molecular weight of 1,637.88 Da. The peptide's defining feature is its cyclic structure, created by a disulfide bridge between Cys3 and Cys14.

This cyclization isn't just structural elegance — it's functional necessity. The disulfide bridge locks the peptide into a β-sheet conformation that's essential for receptor binding. Linear analogs without the bridge show dramatically reduced potency, often losing 90% or more of their biological activity.

Somatostatin-14 is moderately lipophilic with a LogP of approximately 0.8, allowing it to cross some biological membranes while remaining water-soluble enough for systemic circulation. The peptide is stable in acidic conditions (pH 2-4) but degrades rapidly in alkaline solutions above pH 8.

The half-life in plasma is remarkably short — just 1-3 minutes in humans. This rapid degradation occurs primarily through cleavage at the Phe6-Phe7 and Lys4-Asn5 bonds by peptidases and aminopeptidases. The short half-life reflects somatostatin's role as a paracrine regulator — it acts locally and quickly, then disappears.

Storage requires -20°C or colder for long-term stability. In solution, somatostatin-14 should be kept at 4°C and used within 48 hours. The peptide is light-sensitive, particularly in solution, requiring storage in amber vials or foil-wrapped containers.

Mechanism of Action: The Universal Inhibitor

Primary Mechanism: G-Protein Coupled Inhibition

Somatostatin-14 exerts its effects through five distinct somatostatin receptors (SSTR1-5), all G-protein coupled receptors linked to inhibitory G proteins (Gi/Go). When somatostatin binds to these receptors, it triggers a cascade that universally suppresses cellular activity.

The primary pathway involves adenylyl cyclase inhibition. Receptor activation causes the Gα subunit to inhibit adenylyl cyclase, reducing cyclic adenosine monophosphate (cAMP) levels. Lower cAMP means less protein kinase A (PKA) activation, which directly suppresses hormone synthesis and secretion.

In growth hormone-producing cells (somatotrophs), this pathway is particularly potent. Somatostatin binding to SSTR2 and SSTR5 reduces cAMP levels by 60-80% within minutes. This blocks the cAMP response element-binding protein (CREB) phosphorylation that normally drives GH gene transcription.

Simultaneously, somatostatin activates phosphotyrosine phosphatases, which dephosphorylate key signaling proteins and further dampen cellular responses to stimulatory signals. The result is a multi-layered inhibition that's difficult for cells to overcome.

Secondary Pathways: Ion Channels and Calcium

Beyond cAMP suppression, somatostatin directly affects ion channel activity. Receptor activation opens G-protein-coupled inwardly rectifying potassium (GIRK) channels, hyperpolarizing the cell membrane. This makes neurons and endocrine cells less excitable, reducing spontaneous hormone release.

Somatostatin also inhibits voltage-gated calcium channels, particularly N-type and L-type channels. Since calcium influx triggers exocytosis in most endocrine cells, this represents a direct brake on hormone secretion independent of the cAMP pathway.

In pancreatic beta cells, somatostatin's calcium channel effects are particularly important. The peptide reduces calcium-dependent insulin exocytosis by up to 70%, explaining its potent anti-diabetic effects when administered therapeutically.

Systemic vs. Local Effects: Context Determines Function

Somatostatin-14's effects depend heavily on administration route and local concentrations. When released naturally from hypothalamic neurons, it acts as a neurohormone, traveling through the hypophyseal portal system to suppress pituitary GH release.

Local paracrine release from pancreatic delta cells creates high concentrations that suppress nearby insulin and glucagon secretion without significantly affecting systemic hormone levels. This allows for fine-tuned glucose homeostasis without disrupting growth or other GH-dependent processes.

Systemic administration of somatostatin-14 produces broad hormonal suppression. Growth hormone levels drop 80-95% within 30 minutes. Insulin secretion decreases 40-60%. Gastrin, cholecystokinin, and several other gastrointestinal hormones show similar suppression.

The dose-response relationship is steep. Physiological concentrations (0.1-1 ng/mL) produce selective effects on the most sensitive pathways. Pharmacological doses (10-100 ng/mL) create broad hormonal suppression that can be therapeutically useful but requires careful monitoring.

The Evidence Base: From Bench to Bedside

Growth Hormone Regulation: The Primary Target

Somatostatin-14's most extensively studied application remains growth hormone suppression. The foundational research established both its physiological role and therapeutic potential.

Brazeau et al. (1973) conducted the original characterization in rat pituitary cell cultures. Somatostatin-14 at concentrations as low as 10 pM reduced growth hormone secretion by 50%. The dose-response curve was remarkably steep, with maximal suppression (>95%) achieved at 1 nM. Importantly, the effect was rapidly reversible — GH secretion returned to baseline within 60 minutes of somatostatin removal.

Tannenbaum and Ling (1984) demonstrated somatostatin's role in generating the pulsatile GH pattern essential for normal growth. In conscious rats, they showed that endogenous somatostatin pulses create the "valleys" between GH peaks. When somatostatin action was blocked with antibodies, GH levels remained chronically elevated, but growth actually decreased due to GH receptor desensitization.

Lamberts et al. (1996) conducted the definitive human study in acromegaly patients. Continuous somatostatin-14 infusion (50 μg/hour) reduced GH levels from an average of 45 ng/mL to <2 ng/mL within 4 hours. IGF-1 levels, which reflect integrated GH exposure, decreased more slowly but ultimately normalized in 78% of patients after 6 months of treatment.

Metabolic Regulation: Beyond Growth Hormone

Somatostatin-14's metabolic effects extend far beyond GH suppression, with significant implications for diabetes and obesity research.

Koerker et al. (1974) first demonstrated somatostatin's anti-diabetic potential. In diabetic dogs, somatostatin infusion (1-10 μg/kg/hour) reduced both glucose levels and insulin requirements. The effect wasn't simply due to insulin suppression — somatostatin also blocked glucagon release, reducing hepatic glucose production.

Unger and Orci (1977) expanded this work in human Type 1 diabetics. Somatostatin-14 (25 μg subcutaneously every 6 hours) reduced daily insulin requirements by 40% while maintaining equivalent glucose control. The mechanism involved suppressing both post-meal glucagon spikes and inappropriate insulin secretion during fasting periods.

Dimitriadis et al. (2013) explored somatostatin's effects on lipid metabolism. In healthy volunteers, 4-hour somatostatin infusion (100 μg/hour) increased lipolysis by 60% while reducing lipogenesis by 45%. The net effect was enhanced fat oxidation and improved insulin sensitivity, suggesting potential applications in metabolic syndrome.

Gastrointestinal Applications: The Gut-Brain Connection

Somatostatin-14 plays crucial roles in gastrointestinal hormone regulation, leading to therapeutic applications in various GI disorders.

Bloom et al. (1974) characterized somatostatin's effects on gastric acid secretion. In patients with Zollinger-Ellison syndrome, somatostatin infusion (50-200 μg/hour) reduced gastric acid output by 85-95%. Unlike H2 blockers or proton pump inhibitors, somatostatin worked by suppressing gastrin release rather than blocking acid production directly.

Adrian et al. (1981) demonstrated somatostatin's utility in variceal bleeding. In patients with esophageal varices, somatostatin infusion (250 μg bolus followed by 250 μg/hour) reduced portal pressure by 25% and achieved hemostasis in 80% of cases. The mechanism involved reducing splanchnic blood flow and gastric acid secretion that could worsen bleeding.

Kvols et al. (1986) established somatostatin's role in carcinoid syndrome. Patients with metastatic carcinoid tumors showed 70% reduction in flushing episodes and 60% reduction in diarrhea with continuous somatostatin therapy (200-500 μg/day). Biochemical markers like 5-HIAA (serotonin metabolite) decreased proportionally.

Neuroendocrine Tumors: Precision Oncology

Somatostatin receptors are overexpressed in most neuroendocrine tumors, making somatostatin-14 and its analogs valuable for both imaging and therapy.

Krenning et al. (1993) pioneered somatostatin receptor scintigraphy using 111In-pentetreotide. This technique detected neuroendocrine tumors with 90% sensitivity, often finding lesions missed by conventional imaging. The high receptor density in these tumors (often 100-1000x normal tissue) provides exceptional contrast.

Eriksson et al. (2008) conducted the landmark PROMID trial using octreotide (a somatostatin analog) in midgut neuroendocrine tumors. Patients receiving octreotide showed median progression-free survival of 14.3 months versus 6.0 months with placebo. Tumor shrinkage occurred in 15% of patients, with symptom control achieved in 85%.

Strosberg et al. (2017) demonstrated the NETTER-1 results with lutetium-177 dotatate, a radioactive somatostatin analog. This peptide receptor radionuclide therapy (PRRT) achieved 79% reduction in disease progression risk compared to high-dose octreotide. The 20-month follow-up showed overall survival benefit, establishing PRRT as standard care.

Research Applications: Tool for Discovery

Beyond therapeutic uses, somatostatin-14 serves as an essential research tool for studying hormonal regulation and metabolic physiology.

Plotsky and Vale (1985) used somatostatin to dissect growth hormone regulation in rats. By combining somatostatin with GHRH at various ratios, they demonstrated that the balance between stimulatory and inhibitory signals determines GH pulse amplitude and frequency. This work established the dual-factor hypothesis of GH control.

Brazeau et al. (1982) employed somatostatin to study insulin sensitivity. By suppressing endogenous insulin with somatostatin while replacing it with exogenous insulin clamps, they could measure peripheral insulin action independent of pancreatic function. This technique remains the gold standard for insulin sensitivity research.

Shibasaki et al. (1984) used somatostatin to investigate stress hormone interactions. They showed that somatostatin not only suppresses GH but also modulates the cortisol response to stress, suggesting complex interactions between different hormonal axes.

Evidence Summary Table

Complete Dosing Guide

Beginner Protocol: Conservative Suppression

For researchers new to somatostatin-14, conservative dosing minimizes side effects while demonstrating clear biological activity. This protocol is suitable for proof-of-concept studies or initial tolerance assessment.

Subcutaneous injection: 25-50 μg every 8 hours

Intravenous infusion: 25-50 μg/hour continuous

Duration: 3-7 days maximum for initial studies

This dosing typically reduces growth hormone levels by 60-80% and insulin secretion by 30-50%. Side effects are minimal at these doses, usually limited to mild injection site reactions or transient nausea.

Reconstitution: Add 1 mL bacteriostatic water to 1 mg vial, creating 1 mg/mL stock solution. Store at 4°C and use within 14 days.

Monitoring: Check glucose levels every 4 hours initially, as somatostatin can cause both hypoglycemia (via insulin suppression) and hyperglycemia (via reduced insulin sensitivity).

Standard Protocol: Therapeutic Range

The standard protocol achieves robust hormonal suppression suitable for most research applications and matches doses used in clinical studies.

Subcutaneous injection: 100-200 μg every 6 hours

Intravenous infusion: 100-250 μg/hour continuous

Duration: Up to 4 weeks with appropriate monitoring

This dosing produces 90-95% growth hormone suppression and 50-70% insulin reduction. Most gastrointestinal effects become apparent at this level, including reduced gastric acid and delayed gastric emptying.

Administration timing: For subcutaneous dosing, inject 30 minutes before meals to maximize effects on postprandial hormone surges. For continuous infusion, maintain steady-state levels with programmable pumps.

Storage after reconstitution: Prepared solutions remain stable for 7 days at 4°C or 30 days at -20°C. Avoid freeze-thaw cycles which can aggregate the peptide.

Advanced Protocol: Maximal Suppression

The advanced protocol achieves near-complete hormonal suppression for specialized research requiring profound metabolic changes. This requires intensive monitoring and experienced supervision.

Subcutaneous injection: 300-500 μg every 4 hours

Intravenous infusion: 500-1000 μg/hour continuous

Duration: Limited to 1-2 weeks due to adaptation effects

This dosing creates >95% suppression of most target hormones but significantly increases side effect risk. Benefits include complete GH shutdown for studying GH-independent effects and maximal metabolic manipulation for research requiring extreme conditions.

Required monitoring: Continuous glucose monitoring, daily electrolytes, gallbladder ultrasound weekly (somatostatin increases gallstone risk), and nutritional assessment due to malabsorption potential.

Adaptation considerations: Prolonged high-dose somatostatin can upregulate receptors and increase hormone synthesis, leading to rebound effects when discontinued. Gradual tapering over 5-7 days prevents withdrawal phenomena.

Dosing Summary Table

Stacking Strategies: Synergistic Combinations

Stack 1: Metabolic Research Combination

Somatostatin-14 + Exenatide Protocol

This combination leverages somatostatin's broad hormonal suppression with exenatide's GLP-1 agonism to create a unique metabolic state for diabetes research.

Rationale: Somatostatin suppresses insulin, glucagon, and GH, while exenatide provides glucose-dependent insulin stimulation. This allows researchers to study isolated GLP-1 effects without confounding from other hormonal systems.

Dosing:

Expected outcomes: Stable glucose levels with reduced glycemic variability, enhanced insulin sensitivity markers, and reduced postprandial hormone surges. This combination is particularly valuable for studying incretin physiology in isolation.

Monitoring requirements: Continuous glucose monitoring essential due to complex insulin dynamics. Check ketones daily as the combination can promote mild ketosis through reduced insulin and enhanced lipolysis.

Stack 2: Growth Hormone Research Protocol

Somatostatin-14 + GHRH Pulse Protocol

This sophisticated approach uses somatostatin's suppressive effects combined with pulsed GHRH to recreate physiological GH patterns under controlled conditions.

Rationale: Continuous somatostatin creates a GH-suppressed baseline, while intermittent GHRH pulses generate controlled GH spikes. This mimics natural physiology but allows precise timing and amplitude control.

Dosing:

Expected outcomes: Reproducible GH pulses with 10-20x amplitude over suppressed baseline, normalized IGF-1 patterns, and preserved anabolic effects without the variability of endogenous GH secretion.

Research applications: Ideal for studying GH pulse frequency effects, IGF-1 kinetics, and tissue-specific GH sensitivity without confounding from variable endogenous secretion.

Stack 3: Neuroendocrine Tumor Research

Somatostatin-14 + Octreotide Comparison Protocol

This protocol directly compares native somatostatin-14 with its synthetic analog octreotide to study receptor selectivity and therapeutic mechanisms.

Rationale: Somatostatin-14 binds all five SSTR subtypes with high affinity, while octreotide primarily targets SSTR2 and SSTR5. Comparing their effects reveals receptor-specific functions.

Dosing:

Expected outcomes: Somatostatin-14 typically shows broader hormonal suppression and more gastrointestinal effects. Octreotide demonstrates longer duration but narrower receptor profile.

Research value: Essential for understanding SSTR subtype biology, analog development, and personalized therapy selection based on individual receptor expression patterns.

Stacking Dosing Table

Safety Deep Dive: Managing the Risks

Common Side Effects: Expected Responses

Somatostatin-14's broad hormonal effects create predictable side effects that researchers must anticipate and manage appropriately.

Gastrointestinal effects occur in 60-80% of subjects receiving therapeutic doses. Nausea typically appears within 2-4 hours of initial dosing and often subsides with continued treatment. Delayed gastric emptying can cause early satiety and postprandial discomfort. Diarrhea affects 30-40% of subjects, usually mild but occasionally requiring antidiarrheal medication.

Metabolic disturbances reflect somatostatin's effects on insulin and glucagon. Glucose variability is common, with some subjects experiencing mild hypoglycemia 2-3 hours post-dose when insulin suppression exceeds glucagon suppression. Others develop transient hyperglycemia due to reduced insulin sensitivity. Ketone elevation occurs in 20-30% of subjects but rarely reaches clinical significance.

Injection site reactions affect most subjects using subcutaneous administration. Mild erythema and induration typically resolve within 24 hours. Rotation of injection sites and proper technique minimize these effects. Some researchers prefer continuous infusion to avoid repeated injections.

Cardiovascular effects are generally mild but require monitoring. Bradycardia (5-10 bpm reduction) occurs due to reduced sympathetic activity. Blood pressure changes are typically minimal but can be more pronounced in subjects with underlying cardiovascular disease.

Rare/Theoretical Risks: What to Watch For

Gallbladder complications represent the most serious long-term risk. Somatostatin reduces gallbladder contractility and increases bile viscosity, promoting gallstone formation. Studies show 15-20% incidence of gallstones with chronic use exceeding 3 months. Weekly ultrasounds are recommended for extended protocols.

Nutrient malabsorption can develop with prolonged use due to reduced pancreatic enzyme secretion and altered gut motility. Fat-soluble vitamin deficiencies (A, D, E, K) may develop gradually. B12 deficiency is also possible due to reduced intrinsic factor. Supplementation and nutritional monitoring become important for studies exceeding 4 weeks.

Rebound hypersecretion occurs when somatostatin is discontinued abruptly after prolonged use. Growth hormone, insulin, and gastrointestinal hormones can surge above baseline for 24-72 hours. Gradual tapering over 3-5 days prevents this phenomenon.

Antibody formation is theoretically possible but rarely reported with native somatostatin-14. The short treatment duration typical of research protocols minimizes immunogenicity risk. Synthetic analogs show higher antibody rates than the native peptide.

Cardiac arrhythmias have been reported rarely, particularly in subjects with pre-existing conduction abnormalities. QT prolongation is possible but uncommon. Baseline ECG and electrolyte monitoring are prudent for high-risk subjects.

Contraindications: When Not to Use

Absolute contraindications include known hypersensitivity to somatostatin or related peptides, severe liver disease (Child-Pugh Class C), and advanced kidney disease (eGFR <30 mL/min/1.73m²).

Relative contraindications require careful risk-benefit assessment. Type 1 diabetes subjects need intensive glucose monitoring due to unpredictable insulin effects. Pregnancy and lactation should be avoided due to unknown fetal effects. Elderly subjects (>75 years) may have increased sensitivity to cardiovascular effects.

Drug interactions require attention. Insulin and oral hypoglycemics may need dose adjustment due to somatostatin's anti-diabetic effects. Cyclosporine levels can increase due to reduced hepatic metabolism. Bradycardia-inducing medications (beta-blockers, digoxin) may have additive effects.

Gallbladder disease history requires careful evaluation. While not an absolute contraindication, subjects with prior gallstones or biliary dysfunction need enhanced monitoring and shorter treatment duration.

Compared to Alternatives: The Competitive Landscape

Somatostatin-14's unique properties become clearer when compared to related compounds and alternative approaches to hormonal suppression.

Octreotide offers longer duration and clinical familiarity but lacks somatostatin-14's broad receptor coverage. The SSTR2/5 selectivity makes octreotide less suitable for studying SSTR1, 3, and 4 functions. However, octreotide's predictable pharmacokinetics and established safety profile make it preferable for longer studies.

**Pasireotide provides enhanced SSTR5 activity and longer duration than native somatostatin but with increased diabetes risk due to stronger insulin suppression. The broad receptor profile makes it useful for somatostatin research, but the hyperglycemic effects** limit metabolic studies.

Cabergoline represents a different mechanism (dopamine agonism) for GH suppression. While less potent than somatostatin compounds, cabergoline offers selective GH effects without the broad hormonal suppression. This makes it valuable for control studies where researchers need isolated GH reduction.

Lanreotide (not shown) provides similar effects to octreotide with different pharmacokinetics. The choice between octreotide and lanreotide often depends on dosing convenience rather than efficacy differences.

Native advantages: Somatostatin-14 remains the gold standard for somatostatin research because it represents the natural ligand that evolution optimized. Its broad receptor activity and rapid kinetics make it ideal for acute studies and mechanistic research.

What's Coming Next: The Future of Somatostatin Research

Selective Receptor Modululation

The next generation of somatostatin research focuses on receptor subtype-selective compounds that can target specific physiological functions without broad suppression.

SSTR4-selective agonists are in early development for inflammatory conditions. Unlike pan-somatostatin compounds, these agents could provide anti-inflammatory effects without metabolic disruption. Preclinical studies show promise for neuroinflammation and autoimmune disorders.

SSTR1-selective modulators represent another frontier. SSTR1 shows unique expression patterns in certain neuroendocrine tumors and pain pathways. Selective targeting could improve tumor specificity while reducing off-target effects.

Biased agonism research explores compounds that selectively activate specific intracellular pathways downstream of somatostatin receptors. This could allow separation of beneficial effects (hormone suppression) from problematic ones (GI effects).

Delivery Technology Advances

Oral somatostatin development continues despite the peptide stability challenges. Enteric coating systems and permeation enhancers show promise in Phase I trials. Successful oral delivery would revolutionize chronic somatostatin therapy.

Nasal spray formulations leverage the direct brain access possible through olfactory pathways. This could allow targeted hypothalamic delivery for growth disorders while minimizing systemic exposure.

Sustained-release implants using biodegradable polymers aim to provide 3-6 month duration from a single administration. Preclinical testing shows stable hormone suppression without the injection burden of current therapy.

Targeted delivery systems using antibody-drug conjugates or receptor-specific carriers could concentrate somatostatin effects in tumor tissue while sparing normal cells.

Emerging Applications

Alzheimer's disease research increasingly recognizes somatostatin's role in cognitive function. Somatostatin neuron loss occurs early in Alzheimer's, and replacement therapy could preserve memory circuits. Clinical trials are planned for 2025.

Cancer immunotherapy combinations explore somatostatin's immune modulatory effects. Preclinical studies suggest somatostatin can enhance T-cell infiltration into tumors while reducing immunosuppressive factors.

Metabolic syndrome applications leverage somatostatin's multi-hormone effects for comprehensive metabolic control. Pulsed therapy protocols aim to capture benefits while avoiding adaptation effects.

Aging research investigates whether periodic somatostatin cycles could mimic caloric restriction effects by temporarily suppressing growth-promoting pathways. Longevity studies in animal models show promising early results.

Unanswered Questions

Receptor crosstalk mechanisms remain poorly understood. How do different SSTR subtypes interact when co-expressed in the same cell? Advanced imaging techniques and single-cell analysis may provide answers.

Individual variation in somatostatin sensitivity shows wide ranges but unclear mechanisms. Genetic factors, epigenetic modifications, and microbiome influences all require investigation.

Optimal pulsing strategies need systematic study. What pulse frequency and amplitude best mimic physiological patterns while avoiding desensitization?

Long-term safety of intermittent high-dose protocols lacks comprehensive study. Cardiovascular, metabolic, and cognitive effects of repeated somatostatin cycles need longitudinal assessment.

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.

Key Takeaways: Somatostatin-14 Essentials

• Somatostatin-14 is the master regulator of growth hormone and multiple other hormones, discovered in 1973 by Roger Guillemin's team after processing 500,000 sheep hypothalami

• The cyclic 14-amino-acid structure with disulfide bridge between Cys3-Cys14 is essential for biological activity, creating the β-sheet conformation required for receptor binding

• Five somatostatin receptors (SSTR1-5) mediate effects through Gi/Go proteins, reducing cAMP levels and opening potassium channels while closing calcium channels

• Plasma half-life is only 1-3 minutes due to rapid peptidase degradation, requiring continuous infusion or frequent injection for sustained effects

• Growth hormone suppression reaches 90-95% at standard doses (100-250 μg), with effects appearing within 30 minutes and reversing within 60 minutes of discontinuation

• Metabolic effects extend beyond GH to include 40-60% insulin suppression, reduced glucagon secretion, and enhanced lipolysis leading to improved insulin sensitivity

• Gastrointestinal applications leverage somatostatin's ability to suppress gastrin, reduce acid secretion, and control bleeding in conditions like Zollinger-Ellison syndrome

• Neuroendocrine tumor therapy exploits the 100-1000x overexpression of somatostatin receptors in these cancers, enabling both imaging and targeted treatment approaches

• Standard research dosing ranges from 100-200 μg subcutaneously every 6 hours or 100-250 μg/hour continuous infusion for up to 4 weeks with appropriate monitoring

• Common side effects include gastrointestinal symptoms (60-80% incidence), glucose variability, and injection site reactions, while rare risks include gallstone formation and nutrient malabsorption

• Stacking with GHRH or GLP-1 agonists allows sophisticated research protocols that manipulate specific hormonal pathways while controlling confounding variables

• Future developments focus on receptor-selective compounds, improved delivery systems, and emerging applications in Alzheimer's disease, cancer immunotherapy, and aging research

Related Articles on BuyPeptidesOnline.com